Associated Papers
MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.
Jain AP et al.
Scientific Reports, 2019
31827134 (PubMed )
Supplement: 41598_2019_55208_MOESM1_ESM.pdf
Select a paper to view details